Skip to main content
. 2024 Apr 16;15:1381508. doi: 10.3389/fimmu.2024.1381508

Figure 1.

Figure 1

Design of mRNA-LNP for effective production of HA antigens in mammalian cells. (A) Scheme of mRNA with key parts, including 5’ and 3’ UTRs, influenza virus (IV) HA CDS, and poly(A)-tail; (B) Schematic visualization of separately formulated mRNAs encoding influenza HAs from three seasonal (2022-2023) vaccine strains.